{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:54:02Z","timestamp":1791276842390,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100002660","name":"Islamic Azad University","doi-asserted-by":"publisher","award":["8153"],"award-info":[{"award-number":["8153"]}],"id":[{"id":"10.13039\/501100002660","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Rosacea is a chronic, multifactorial, dermatological condition. Increased density of\n                      <jats:italic>Demodex folliculorum<\/jats:italic>\n                      mites in the skin of rosacea patients suggests a possible role for these mites in the pathophysiology of rosacea.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To evaluate the effects of permethrin 5% topical gel vs. placebo on\n                      <jats:italic>Demodex<\/jats:italic>\n                      density (Dd) and clinical presentations of rosacea patients, and also to further refine the quantitative assessment of Dd in the non\u2010invasive standard skin surface biopsy (\n                      <jats:styled-content style=\"fixed-case\">SSSB<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twenty patients with bilateral papulopustular rosacea and \u22655 mites\/cm\n                      <jats:sup>2<\/jats:sup>\n                      were enrolled in the study. Participants and physicians were blinded to the group assignments. Each patient applied permethrin on one side and placebo on the other side of the face twice daily for 12 weeks.\n                      <jats:styled-content style=\"fixed-case\">SSSB<\/jats:styled-content>\n                      and photography and Rosacea Clinical Scorecard of the National Rosacea Society were used to assess the patients at the baseline, 2nd, 5th, 8th, and 12th weeks for both sides of the face. Causality and severity of adverse drug reactions (\n                      <jats:styled-content style=\"fixed-case\">ADR<\/jats:styled-content>\n                      s) were assessed by\n                      <jats:styled-content style=\"fixed-case\">WHO<\/jats:styled-content>\n                      Scale and Hartwig Scale, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Dd was not significantly different between the two groups at the baseline. In both groups, Dd significantly decreased after 12 weeks compared to the baseline. At the end of the 12th week, the Dd in the permethrin group was significantly lower than the placebo group. Severity of the clinical presentations decreased in both groups at the end of week 12 in comparison to the baseline, particularly in the permethrin group.\n                      <jats:styled-content style=\"fixed-case\">ADR<\/jats:styled-content>\n                      s were all mild and in most cases unlikely related to permethrin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Permethrin 5% gel can significantly reduce the Dd and severity of presentations in rosacea patients and can be a safe and effective option in the management of this chronic disorder. This new\n                      <jats:styled-content style=\"fixed-case\">SSSB<\/jats:styled-content>\n                      technique offers an easy, quick, inexpensive, and non\u2010invasive sampling method proper for quantitative assessment of Dd.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.13801","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T06:20:22Z","timestamp":1473229222000},"page":"2105-2117","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of permethrin 5% topical gel vs. placebo for rosacea: a double\u2010blind randomized controlled clinical trial"],"prefix":"10.1111","volume":"30","author":[{"given":"K.","family":"Raoufinejad","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Faculty of Pharmacy Pharmaceutical Sciences Branch Islamic Azad University Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mansouri","sequence":"additional","affiliation":[{"name":"Skin and Stem Cell Research Center Tehran University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rajabi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Faculty of Pharmacy Pharmaceutical Sciences Branch Islamic Azad University Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Naraghi","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Pathology Tehran University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jebraeili","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tehran Medical Branch Islamic Azad University Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"38","article-title":"Rosacea: a review","volume":"34","author":"Culp B","year":"2009","journal-title":"Pharm Ther"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120625"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000082564"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70065-2"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1998.00218.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.05.034"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb00261.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.00331.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1998.tb01739.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1971.tb06853.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02125.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09645.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.335"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02940.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065849"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2004.tb00567.x"},{"key":"e_1_2_7_18_1","first-page":"177","article-title":"A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea","volume":"56","author":"Signore RJ","year":"1995","journal-title":"Cutis"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.03794.x"},{"key":"e_1_2_7_20_1","article-title":"Interventions for rosacea","author":"Zuuren EJ","year":"2011","journal-title":"The Cochrane Library, February"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-11-201006010-00232"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.004"},{"key":"e_1_2_7_23_1","unstructured":"ICMJE.Recommendations for the conduct reporting editing and publication of scholarly work in medical journals. [WWW document]2013. URLwww.icmje.org(last accessed: 24 April 2014)."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"e_1_2_7_25_1","unstructured":"WHO\u2013UMC.The use of the WHO\u2010UMC system for standardised case causality assessment. Uppsala Sweden: UMC. [WWW document]2000. URLhttp:\/\/who-umc.org\/Graphics\/24734.pdf(last accessed: 29 July 2013)."},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1093\/ajhp\/49.9.2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig SC","year":"1992","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.15.2000"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02471.x"},{"key":"e_1_2_7_29_1","unstructured":"Lexicomp.Permethrin: drug information. UpToDate2014."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0932-7"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1930.01440070027002"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.3.448.61596"},{"key":"e_1_2_7_33_1","author":"EMEA","year":"1998","journal-title":"European Agency for the Evaluation of Medicinal Products"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/10408449009089874"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02455.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13801","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.13801","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:37:35Z","timestamp":1791275855000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/jdv.13801"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13801","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]}}}